Antiprotozoal agents
Dr. Pravin Prasad
M.B.B.S., MD Clinical Pharmacology
Assistant Professor, Maharajgunj Medical College
14 November 2021 (28 Kartik 2078), Sunday
By the end of the class, MBBS 2nd
year students will be able to:
List the common protozoal infections in humans
Understand the life cycle of common protozoa
Explain the pharmacotherapeutic management of
amoebiasis and giardiasis
Common Protozoal infections
in humans
Condition Infecting agent
Amoebiasis Entamoeba histolytica
Giardiasis Giardia Lambia
Trichomoniasis Trichomonas vaginalis
Malaria Plasmodium sps.
Leishmaniasis Leishmania donovani
Toxoplasmosis Toxoplasma gondii
Trypanosomiasis T. cruzi, T. brucei gambiense, T.
brucei rhodesiense
Life cycle of E. histolytica
Life cycle of G. lambia
Classification: Anti-amoebic
drugs
Tissue amoebicides Luminal amoebicides
For intestinal and
extraintestinal
amoebiasis
For extraintestinal
amoebiasis
Nitroimidazole
s
Metro-, Tini- Secni-,
Satrani-dazole
Alkaloids
(Dehydro)Emetine
Chloroquine
Classification: Anti-amoebic
drugs
Tissue amoebicides Luminal amoebicides
Amides Diloxanide furoate, Nitazoxanide
8-
hydroxyquinolines
Quiniodochlor,
Iodoquinol
Antibiotics
Tetracycline,
Paromomycin
Drugs Used in Giardiasis
Nitroimidazole
Metronidazole, Tinidazole, Secnidazole
Amides
Nitazoxanide
8-hydroxyquinolones
Quiniodochlor
Nitroimidazoles
Metronidazole, Tinidazole, Secnidazole
Mechanism of action:
Enters cells and gets reduced to highly reactive
nitro radical
Competes for electrons with electron acceptors
generated by pyruvate-ferredoxin oxidoreductase
(PFOR)
•Acts as electron-sink
Energy metabolism disrupted  Cytotoxic effect
Metronidazole: Adverse effects
Most common:
Anorexia, nausea, metallic taste and abdominal
cramps, looseness of stool
Urticaria, flushing, heat, itching, rashes and
fixed drug eruption occur in allergic subjects
Metronidazole: Indications
Amoebiasis
Giardiasis
Trichomonas vaginitis
Anaerobic bacterial infections
Pseudomonas enterocolitis
Acute necrotizing ulcerative gingivitis (ANUG)
Helicobacter pylori gastritis/peptic ulcer
Antiprotozoal agents- II
Dr. Pravin Prasad
M.B.B.S., MD Clinical Pharmacology
Assistant Professor, Maharajgunj Medical College
17 November 2021 (1 Mangsir 2078), Wednesday
Classification: Anti-amoebic
drugs
Tissue amoebicides Luminal amoebicides
For intestinal and
extraintestinal
amoebiasis
For extraintestinal
amoebiasis
Nitroimidazole
s
Metro-, Tini- Secni-,
Satrani-dazole
Alkaloids
(Dehydro)Emetine
Chloroquine
Classification: Anti-amoebic
drugs
Tissue amoebicides Luminal amoebicides
Amides Diloxanide furoate, Nitazoxanide
8-
hydroxyquinolines
Quiniodochlor,
Iodoquinol
Antibiotics
Tetracycline,
Paromomycin
Alkaloids
Emetine, Dehydroemetine
Potent and directly acting amoebicides
Kills trophozoites
Cysts not affected
Acts by inhibiting intra-ribosomal translocation of
tRNA-amino acid complex
Administered by s.c. or i.m. injection
Alkaloids
Emetine: side effects
Local irritant
Systemic toxicity:
•Nausea,vomitting, abdominal cramps, diarrhoea
•Weakness, stiffness of muscles, myositis
•Hypotension, ECG changes, myocarditis
Dehydroemetine: less toxic
Alkaloids
Acute amoebic dysentery and amoebic liver abscess
In patients not tolerating metronidazole
Followed by luminal amoebicide
Chloroquine
Active against trophozoites of E. histolytica and
gets highly concentrated in liver
Completely absorbed in upper intestine
Longer duration of treatment required
Higher relapse rate
Chloroquine
Uses:
Amoebic liver abscess
600mg (base) for two days, followed by 300mg
base daily for 2-3 weeks
•Should be combined with luminal amoebicides
Side effects:
Nausea, vomitting, anorexia
Difficulty in accommodation, headache
Diloxanide furoate
Highly effective luminal amoebicides
Kills trophozoites
Diloxanide furoate (DF) is more effective
Unabsorbed fraction reaching the intestine
responsible for therapeutic effect
DF  hydrolysed by esterases into diloxanide
Absorbed, no therapeutic activity seen
Glucuronide conjugated, eliminated by kidneys
Diloxanide furoate
Uses:
Intestinal amoebiasis
Asymptomatic cyst passers
After or along tissue amoebicides
Adverse effects:
Flatulence, occasional nausea, itching and rarely
urticaria
Nitazoxanide
Prodrug
Active form- tizoxanide
Acts by inhibiting Pyruvate: ferredoxin
oxidoreductase (PFOR)
Is active against:
Protozoans- E. histolytica, T. vaginalis, G.
lambia, Cryptosporidium
Helminthes- A. lumbricoides, H. nana
Nitazoxanide
Indications:
Cryptosporidium infection
Giardiasis (metronidazole resistant as well)
E. histolytica (luminal amoebicide)
Side effects:
Abdominal pain, vomitting, headache
Quiniodochlor
Luminal agents (8-hydroxyquinolines)
Active against:
Protozoa
Fungi (Candida)
Bacteria
Active against the cysts present in the lumen
Quiniodochlor
Indications:
Intestinal amoebiasis
Giardiasis
Monilial and trichomonas vaginitis (local
treatment)
Fungal and bacterial skin infection
Quiniodochlor
Adverse effects:
Nausea, transient loose and green stools
Pruritis
Iodism, goiter
Acute reactions: fever with chills, angioedema,
cutaneous haemorrhage
Prolonged/continuous use:
•Subacute myelo-optic neuropathy (SMON)
Tetracycline
Adjuvant role
Modest direct inhibitory action on E. histolytica
Older tetracyclines reaches colon in large amounts
Inhibit bacterial flora (symbiotic relation with E.
histolytica)
Indirect inhibition of E. histolytica
Uses: chronic amoebiasis with only luminal
infection
Paromomycin
Aminoglycoside antibiotic
Active against protozoa and helminths as well
For intestinal amoebiasis, should be given orally
No absorption
No metabolism
Eliminated unchanged in faeces
Paromomycin
Uses:
Amoebiasis
Giardiasis
Cryptosporidiosis
Leishmaniasis
• 500mg three times
a day for 7 days
• Children 10mg/kg
Treatment: Amoebic infections
Acute amoebic dysentery
Either:
•Tab. Metronidazole 800mg, oral, three times a day
for 7-10 days
•Inj. Metronidazole 500mg, i.v., four times a day till
oral therapy can be instituted
•Tab. Tinidazole 2g, oral, once a day for 3-6 days
And:
•Tab. Diloxanide furoate 500mg, oral, three times a
day for 5-10 days
Treatment: Amoebic infections
Mild intestinal amoebic dysentery
Either:
•Tab. Metronidazole 400mg, oral, three times a
day for 5-7 days
•Tab. Tinidazole 2g, oral, once a day for 2-3 days
And:
•Tab. Diloxanide furoate 500mg, oral, three times
a day for 5-10 days
Treatment: Amoebic infections
Amoebic liver abscess
Either:
• Tab. Metronidazole 800mg, oral, three times a day for 10 days
• Inj. Metronidazole 500mg, i.v. infusion, four times a day for
10days
• Tab. Tinidazole 2g, oral, once a day for 2-3 days
• Inj. Tinidazole 800mg, i.v., daily for 6 days or till oral can be
given
And:
• Tab. Diloxanide furoate 500mg, oral, three times a day for 5-
10 days
Treatment regimens in
Giardiasis
Metronidazole 400 mg, three times a day for 5-7
days OR 2g, once daily for 3 days
Children 15mg/kg/day in three divided doses
Tinidazole 2g single oral dose OR 600 mg once
daily for 7 days
Secnidazole 2g, single oral dose
Treatment regimens in
Giardiasis
Nitazoxanide:
500 mg, twice daily for 3 days
•Children 7.5mg/kg
Quiniodochlor:
250 mg, three times a day for 7 days
Conclusion
Though there are plenty of protozoal infections, only few are
known to cause disease in humans
Depending on the species, protozoa can have intestinal as
well as extra-intestinal stages in their life cycles
Important pharmacotherapeutically
Tissue as well as luminal amoebicides are important for
amoebiasis
Three groups of drugs are available for the treatment of
giardiasis
Nitroimidazole is the treatment of choice for giardiasis
Thank you

Antiprotozoal for MBBS 2021

Editor's Notes

  • #14 Aerobic environment attenuates cytotoxicity of metronidazole by inhibiting its reductive activation O2 competes with nitro radical of metronidazole for the free electrons generated by PFOR Mechanism of resistance: deficient in generation of nitro radical, lower levels of PFOR
  • #15 Relatively frequent and unpleasant, but mostly non serious Urticaria, flushing, heat, itching, rashes and fixed drug eruption occur in allergic subjects, warrant discontinuation of the drug and preclude future use of nitroimidazoles.